Dr Mira Duncalf, MD in Cos Cob, CT - Anesthesiology

Dr Mira Duncalf, MD is a Anesthesiology physician based in Cos Cob, Connecticut. Dr Mira Duncalf is licensed to practice in Connecticut (license number 23212) and her current practice location is 33 Ferncliff Rd, Cos Cob, Connecticut. She can be reached at her office (for appointments etc.) via phone at (203) 661-1762.

NPI number for Dr Mira Duncalf is 1942457718 and her current mailing address is 33 Ferncliff Rd, Cos Cob, Connecticut. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1942457718.

Contact Information

	Dr Mira Duncalf, MD
	33 Ferncliff Rd, Cos Cob, CT 06807-1206
	(203) 661-1762
	(203) 661-1762

Physician's Profile

Full Name	Dr Mira Duncalf
Gender	Female
Speciality	Anesthesiology
Location	33 Ferncliff Rd, Cos Cob, Connecticut
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1942457718
Provider Enumeration Date: 08/25/2008
Last Update Date: 08/25/2008

Medical Identifiers

Medical identifiers for Dr Mira Duncalf such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1942457718	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207L00000X	Anesthesiology	23212 (Connecticut)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Mira Duncalf is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Mira Duncalf, MD 33 Ferncliff Rd, Cos Cob, CT 06807-1206 Ph: (203) 661-1762	Dr Mira Duncalf, MD 33 Ferncliff Rd, Cos Cob, CT 06807-1206 Ph: (203) 661-1762

News Archive

FDA changes policies regarding advisory committees

The Food and Drug Administration today announced several improved policies and procedures strengthening its management of FDA advisory committees. The improvements include stricter limits on financial conflicts of interest for committee members, improved voting procedures, and improvements to the processes for disclosing information pertaining both to advisory committee members and to specific matters considered at advisory committee meetings.

Researchers find 'missing' genetic risk in cancer

A new study could help to answer an important riddle in our understanding of genetics: why research to look for the genetic causes of common diseases has failed to explain more than a fraction of the heritable risk of developing them.

RA synthetic derivative 4-HPR's ability to induce tumour cell death

Retinoic acid (RA), a natural derivative of vitamin A, is the basis of a number of treatments against cancer. Nevertheless, it has certain disadvantages, such as the possibility of the appearance of retinoic acid syndrome, present in 25 % of cases and which can lead to death. The development of 4-HPR, a synthetic derivative of RA, has meant a considerable advance due to its greater efficacy compared to its predecessor.

Recycling existing drugs may help fight several types of cancer

Researchers at the University of Bergen have discovered that a drug against kidney cancer possibly can fight several types of cancer.

PulmoFlow's nebulized drug and device combination gets FDA approval for cystic fibrosis

On Tuesday, the FDA granted final approval of PulmoFlow, Inc.'s New Drug Application for Kitabis Pak – a co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS Nebulizer. This is the first nebulized drug and device combination to be approved for patients with cystic fibrosis.

Dr Mira Duncalf, MD - Anesthesiology in Cos Cob, CT